bluebird bio, Inc. (BLUE)
NASDAQ: BLUE · Real-Time Price · USD
4.090
-0.250 (-5.76%)
Apr 23, 2025, 4:00 PM EDT - Market closed
bluebird bio Revenue
In the year 2024, bluebird bio had annual revenue of $83.81M with 184.12% growth. bluebird bio had revenue of $38.52M in the quarter ending December 31, 2024, with 391.72% growth.
Revenue (ttm)
$83.81M
Revenue Growth
+184.12%
P/S Ratio
0.47
Revenue / Employee
$337,931
Employees
248
Market Cap
40.04M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
BLUE News
- 7 days ago - bluebird bio confirms that Ayrmid, Ltd. has not delivered a binding offer or obtained necessary financing despite extensive engagement - Business Wire
- 23 days ago - Gene Therapy-Focused Bluebird Bio Receives Rival Takeover Offer, Stock Jumps - Benzinga
- 26 days ago - Bluebird bio receives non-binding bid for up to $110.5 million - Reuters
- 26 days ago - Bluebird Bio Reviewing Buyout Offer From Ayrmid for Up to $110.5 Million -- Update - Market Watch
- 26 days ago - bluebird bio Confirms Receipt of an Unsolicited Non-Binding Proposal from Ayrmid - Business Wire
- 5 weeks ago - BLUEBIRD BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of bluebird bio, Inc. - BLUE - Business Wire
- 2 months ago - ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of bluebird bio, Inc. - PRNewsWire
- 2 months ago - Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker - CNBC